Ketamine-assisted therapy is increasingly used for treatment-resistant depression, but safety depends on setting, patient factors, and the specific protocol. Clinical trials and regulatory decisions show that when administered in controlled medical settings, ketamine and its S-enantiomer esketamine can offer rapid symptom relief while producing predictable and manageable acute effects. The early randomized trials led by Carlos A. Zarate Jr. National Institute of Mental Health demonstrated rapid antidepressant effects of single low-dose intravenous ketamine, informing later clinical practice. John H. Krystal Yale School of Medicine and colleagues have described both therapeutic mechanisms and safety considerations observed across studies.
Clinical evidence and acute safety
Acute adverse effects commonly reported in trials include dissociation, transient increases in blood pressure and heart rate, nausea, and sedation. These effects typically peak during or shortly after infusion and resolve within hours. The U.S. Food and Drug Administration approved intranasal esketamine for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy known as REMS to ensure administration in certified clinics with monitoring for sedation and dissociation. This regulatory framework reflects the consensus that supervised administration reduces immediate safety risks. Patients with uncontrolled cardiovascular disease or active psychotic disorders are usually excluded from trials and clinical programs because of higher risk.
Long-term risks, misuse, and access
Long-term safety data remain limited. Observational reports and case series outside clinical settings link high-dose, frequent recreational ketamine use to bladder toxicity and cognitive complaints, suggesting potential risks with chronic, unsupervised exposure. There is also a recognized abuse potential, which informs clinical guidelines emphasizing controlled dosing, screening for substance use disorder, and follow-up. Ongoing studies at academic centers and national institutes aim to clarify durability of benefit and long-term adverse effects, but definitive long-term safety profiles are not yet established.
Cultural and territorial nuances shape risk and benefit: access to certified clinics varies by region, creating disparities in who can receive monitored therapy; cost and insurance coverage affect uptake; and different countries regulate medical ketamine differently. Clinically, the most meaningful consequence is that ketamine can rapidly reduce suicidal ideation for some patients, offering a critical window for further psychotherapy and standard antidepressant strategies. Overall, ketamine-assisted therapy can be relatively safe in medically supervised programs but requires careful patient selection, monitoring, and attention to long-term unknowns.